KRYS Krystal Biotech Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: KRYS

Price (delayed)

$341.75

Market cap

$10.12B

P/E Ratio

41.32

Dividend/share

N/A

EPS

$8.27

Enterprise value

$9.7B

Sign up for free to view scoring metrics ?
Relative Growth: Rel. Growth:
Relative Strength: Rel. Strength:
Relative Valuation: Rel. Valuation:
Relative Profitability: Rel. Profitability: 98

Krystal Biotech, Inc. is a commercial-stage biotechnology company focused on the discovery, development and commercialization of genetic medicines to treat diseases with high unmet medical needs. VYJUVEK ® is the ...

Highlights
The net income has soared by 65% YoY and by 7% from the previous quarter
The EPS has soared by 62% YoY and by 7% from the previous quarter
KRYS's price to earnings (P/E) is 22% higher than its last 4 quarters average of 34.7
The company's quick ratio fell by 15% YoY and by 12% QoQ
Sector: Healthcare
Industry: Biotechnology
Website: http://www.krystalbio.com
Peers: OLMA OMER VIVS ORIC

Key stats

What are the main financial stats of KRYS

KRYS stock price

How has the Krystal Biotech stock price performed over time
Intraday
-2.6%
1 week
1.51%
1 month
-1.39%
1 year
107.16%
YTD
38.62%
QTD
-8.05%

Financial performance

How have Krystal Biotech's revenue and profit performed over time
Revenue
$440.48M
Gross profit
$416.87M
Operating income
$197.75M
Net income
$241.47M
Gross margin
94.6%
Net margin
54.8%
The net income has soared by 65% YoY and by 7% from the previous quarter
The operating income has grown by 42% YoY and by 11% from the previous quarter
The net margin has grown by 34% YoY
The gross profit rose by 24% YoY and by 6% QoQ

Price vs fundamentals

How does KRYS's price correlate with its fundamentals

Growth

What is Krystal Biotech's growth rate over time

Valuation

What is Krystal Biotech stock price valuation
KRYS P/E details
P/E
41.32
P/B
7.41
P/S
22.91
EV/EBIT
42.79
EV/EBITDA
41.57
EV/Sales
22.01
The EPS has soared by 62% YoY and by 7% from the previous quarter
KRYS's price to earnings (P/E) is 22% higher than its last 4 quarters average of 34.7
KRYS's P/B is 62% above its 5-year quarterly average of 4.7 and 25% above its last 4 quarters average of 6.1
Krystal Biotech's equity has increased by 31% YoY and by 6% QoQ
The P/S is 25% above the last 4 quarters average of 18.8
The revenue has grown by 23% year-on-year and by 6% since the previous quarter

Efficiency

How efficient is Krystal Biotech business performance
Krystal Biotech's ROA has increased by 28% YoY
The ROE has grown by 27% YoY
The ROS has grown by 9% YoY and by 3.4% from the previous quarter
Krystal Biotech's return on invested capital has increased by 4.9% YoY

Dividends

What is KRYS's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for KRYS.

Financial health

How did Krystal Biotech financials performed over time
The total liabilities has grown by 45% YoY and by 18% from the previous quarter
The company's total assets rose by 32% YoY and by 7% QoQ
The debt is 99% less than the equity
Krystal Biotech's equity has increased by 31% YoY and by 6% QoQ
The debt has contracted by 9% YoY and by 2.8% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.